Phase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML)
Latest Information Update: 16 Jan 2025
At a glance
- Drugs Cytarabine (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary) ; Ivosidenib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
- Focus Adverse reactions
Most Recent Events
- 13 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 11 May 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2028.
- 11 May 2023 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2026.